The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
UB‐311, a novel UBITh ® amyloid β peptide vaccine for mild Alzheimer's disease
Open accessAbstract
Introduction: A novel amyloid β (Aβ) synthetic peptide vaccine (UB‐311) has been evaluated in a first‐in‐human trial with patients of mild‐to‐moderate Alzheimer's disease. We describe translational research covering vaccine design, preclinical characterization, and phase‐I clinical trial with supportive outcome that advances UB‐311 into an ongoing phase‐II trial. Methods: UB‐311 is constructed with two synthetic Aβ 1–14 –targeting peptides (B‐cell epitope), each linked to different helper T‐cell peptide epitopes (UBITh ® ) and formulated in a Th2‐biased delivery system. The hAPP751 transgenic mouse model was used to perform the proof‐of‐concept study. Baboons and macaques were used for preclinical safety, tolerability, and immunogenicity evaluation. Patients with mild‐to‐moderate Alzheimer's disease (AD) were immunized by intramuscular route with 3 doses of UB‐311 at weeks 0, 4, and 12, and monitored until week 48. Safety and immunogenicity were assessed per protocol, and preliminary efficacy was analyzed by Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog), Mini–Mental State Examination (MMSE), and Alzheimer's Disease Cooperative Study–Clinician's Global Impression of Change (ADCS‐CGIC). Results: UB‐311 covers a diverse genetic background and facilitates strong immune response with high responder rate. UB‐311 reduced the levels of Aβ 1–42 oligomers, protofibrils, and plaque load in hAPP751 transgenic mice. Safe and well‐tolerated UB‐311 generated considerable site‐specific (Aβ 1–10 ) antibodies across all animal species examined. In AD patients, UB‐311 induced a 100% responder rate; injection site swelling and agitation were the most common adverse events (4/19 each). A slower rate of increase in ADAS‐Cog from baseline to week 48 was observed in the subgroup of mild AD patients (MMSE ≥ 20) compared with the moderate AD subgroup, suggesting that UB‐311 may have a potential of cognition improvement in patients with early stage of Alzheimer's dementia. Discussion: The UBITh ® platform can generate a high‐precision molecular vaccine with high responder rate, strong on‐target immunogenicity, and a potential of cognition improvement, which support UB‐311 for active immunotherapy in early‐to‐mild AD patients currently enrolled in a phase‐II trial ( NCT02551809 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Six active immunotherapy agents are currently studied in phase 1, 2, and 3 clinical trials:”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [63]
In the citing paper
“Lu AF20513 epitope vaccine is estimated in a phase 1 study in mild AD.63”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., Burton, M. A., Goldstein, L. E., Duong, S., Tanzi, R. E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009505 · Cited by 1,060
Kumar, D. K. V., Choi, S. H., Washicosky, K. J., Eimer, W. A., Tucker, S., Ghofrani, J., Lefkowitz, A., McColl, G., Goldstein, L. E., Tanzi, R. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1059 · Cited by 971
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512
Molecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna‐Reeves, C. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129001 · Cited by 440
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease
Monsonego, A., Zota, V., Karni, A., Krieger, J. I., Bar-Or, A., Bitan, G., Budson, A. E., Sperling, R., Selkoe, D. J., & Weiner, H. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318104 · Cited by 367
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356
Inflammaging as a prodrome to Alzheimer's disease
Giunta, B., Fernandez, F., Nikolic, W. V., Obregon, D., Rrapo, E., Town, T., & Tan, J. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-51 · Cited by 327
Winblad, B. G., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 321
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · cited 1×
“The last two decades have seen robust development of disease-modifying, passive, and active anti-Ab immunotherapy [5,13,14,41,42]; however, there has been very limited convincing clinical benefits of cognitive improvement [13,38].”
BackgroundZempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.207 · Cited by 283
Models of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-51 · Cited by 256
Parajuli, B., Sonobe, Y., Horiuchi, H., Takeuchi, H., Mizuno, T., & Suzumura, A. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.503 · Cited by 232
Amyloidosis and Alzheimer’s disease
Ghiso, J. A., & Frangione, B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00149-7 · Cited by 191
Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease
Seward, M. E., Swanson, E., Norambuena, A., Reimann, A., Cochran, J. N., Li, R., Roberson, E. D., & Bloom, G. S. (2013) · Journal of Cell Science · doi:10.1242/jcs.1125880 · Cited by 178
The Toxicity of Amyloid ß Oligomers
Zhao, L. N., Leong, H., Mu, Y., & Chew, L. Y. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13067303 · Cited by 163
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
Farlow, M. R., Andreasen, N., Riviere, M., Voštiar, I., Vitaliti, A., Sóvágó, J., Caputo, A., Winblad, B. G., & Graf, A. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0108-3 · Cited by 149
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Vandenberghe, R. R., Riviere, M., Caputo, A., Sóvágó, J., Maguire, R. P., Farlow, M. R., Marotta, G., Sánchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 146
Effective synthetic peptide vaccine for foot-and-mouth disease in swine
Wang, C. Y., Chang, T. Y., Walfield, A. M., John Ye, A., Shen, M., Chen, S. P., Li, M. C., Lin, Y. L., Jong, M. H., Yang, P. C., et al. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00148-2 · Cited by 145
Self-citationPeripheral Chemokine Receptors, Their Ligands, Cytokines and Alzheimer's Disease
Reale, M., Iarlori, C., Feliciani, C., & Gambi, D. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14203 · Cited by 109
Pasquier, F., Sadowsky, C., Holstein, A. R., Prince, G. L., Peng, Y., Jackson, N. M., Fox, N. C., Ketter, N., Liu, E., Ryan, J. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150376 · Cited by 108
Alzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108 · cited 1×
“Ab is the principal target of late-stage development programs with relatively few agents in clinical trials for AD, suggesting a need to amplify the drug discovery ecosystem [17].”
BackgroundSite-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T.-Y., Fang, X. D., Hung, C. H., Hutter-Paier, B., & Windisch, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.031 · Cited by 98
Self-citationPellicanò, M., Bulati, M., Buffa, S., Barbagallo, M., Di Prima, A., Misiano, G., Picone, P., Di Carlo, M., Nuzzo, D., Candore, G., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091714 · Cited by 86
Ghochikyan, A., Mkrtichyan, M., Petrushina, I., Movsesyan, N., Karapetyan, A., Cribbs, D. H., & Agadjanyan, M. G. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.039 · Cited by 81
Bouter, Y., López‐Noguerola, J. S., Tucholla, P., Crespi, G. A. N., Parker, M. W., Wiltfang, J., Miles, L. A., & Bayer, T. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1489-x · Cited by 74
Agadjanyan, M. G., Petrovsky, N., & Ghochikyan, A. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1884 · Cited by 65
Developing therapeutic vaccines against Alzheimer’s disease
Wısnıewskı, T., & Drummond, E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 60
Reiman, E. M. (2016) · Nature · doi:10.1038/537036a · Cited by 53
Qian, X., Hamad, B., & Dias-Lalcaca, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4749 · Cited by 52
Alzheimer disease's double-edged vaccine
Greenberg, S. M., Bacskai, B. J., & Hyman, B. T. (2003) · Nature Medicine · doi:10.1038/nm847 · Cited by 51
Marciani, D. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13608 · Cited by 48
Alzheimer's disease vaccine development: A new strategy focusing on immune modulation
Marciani, D. J. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.08.008 · Cited by 45
Synthetic IgE peptide vaccine for immunotherapy of allergy
Wang, C. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00732-6 · Cited by 38
Self-citationSynthetic AIDS vaccine by targeting HIV receptor
Wang, C. Y., Shen, M., Tam, G., Fang, X. D., John Ye, A., Shen, F., Walfield, A. M., Wang, J. J. G., Li, M. L., Li, X. M., et al. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00432-2 · Cited by 29
Self-citationWang, C. C., & Walfield, A. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.007 · Cited by 26
Self-citationSavage, M. J., Wu, G., McCampbell, A., Wessner, K., Citron, M. P., Liang, X., Hsieh, S., Wolfe, A. L., Kinney, G. G., Rosen, L. B., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.437 · Cited by 15
Hendrix, S. B., Ellison, N., Stanworth, S. H., Tierney, L. K., Mattner, F., Schmidt, W., Dubois, B., & Schneeberger, A. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.67 · Cited by 13
Flagged first, then by citations
Cited by
Sorted by citations
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domínguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 680
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Metadata
- Authors
- Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., Tseng, Y., Peng, W., Wang, J., Yu, C., Kuo, B., & Frohna, P. A.
- Affiliations
- United Biomedical (United States) (US)
- Taipei Veterans General Hospital (TW)
- National Taiwan University Hospital (TW)
- United Biomedical Inc. Asia (UBI‐Asia) Hsinchu Taiwan
- United Biomedical, Inc. (UBI) Hauppauge NY USA
- United Neuroscience, Inc. (UNS) Hsinchu Taiwan
- Corresponding author
- Wang, Chang Yi
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2017-04-14
- Volume
- 3
- Issue
- 2
- Pages
- 262-272
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC5651432
- OpenAlex
- W2605942834
- Cited by
- 150
- References
- 52
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 19 · 2023: 19 · 2022: 20 · 2021: 18 · 2020: 20 · 2019: 16 · 2018: 7
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- United Biomedical, Inc., Hauppauge, New York
- United Biomedical, Inc., Asia, Taiwan
- Ministry of Economic Affairs Grant, Taiwan
- UBITh AD Immunotherapeutic Vaccine [UB-311] (98-EC-17-A-20-1-0014)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, mild to moderate Alzheimer's disease, B-cell epitopes, helper T cell epitopes, immunogenicity, vaccine safety, amyloid plaques, baboons, macaque
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
